Press release
Peptide Based Metabolic Disorders Therapeutics Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth
Peptide Based Metabolic Disorders Therapeutics
How Large Will the Peptide Based Metabolic Disorders Therapeutics Market Size By 2025?
The market size of peptide-based metabolic disorder treatments has been rapidly expanding in recent years. It's projected to swell from $29.89 billion in 2024 to $34.4 billion in 2025 with a compound annual growth rate (CAGR) of 15.1%. The growth witnessed in the past period can be ascribed to factors such as rising healthcare spending, the surge in metabolic disorder cases, advances in peptide synthesis techniques, an aging population, expansion of the biopharmaceutical sector, regulatory green lights for novel therapies, and heightened awareness of personalized medicines.
How Big Is the Peptide Based Metabolic Disorders Therapeutics Market Size Expected to Grow by 2029?
It is projected that the peptide-based metabolic disorders therapeutics market will experience significant expansion in the coming years, potentially reaching $59.85 billion in 2029 with a compound annual growth rate (CAGR) of 14.8%. This growth in the predicted timeframe can be accredited to the emergence of new peptide analogs, increased funding in metabolic disorder research and development initiatives, adoption of precision medical practices, and the surge of emerging markets. Additional contributing factors include partnerships in drug development, advancements in delivery methods, and a focus on patient-centered treatments. Forecasts for the market are also influenced by a variety of trends, including the use of artificial intelligence (AI) in drug discovery, the escalation of personalized treatments, the application of CRISPR/Cas9 for gene therapies, the inclusion of wearable devices in patient monitoring, the formulation of oral peptides, the inclusion of digital therapies in disease management, and the utilization of biobanking for tailored treatments.
View the full report here:
https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report
Which Key Market Drivers Powering Peptide Based Metabolic Disorders Therapeutics Market Expansion and Growth?
The increasing instances of obesity are anticipated to fuel the expansion of the peptide-based metabolic disorders therapeutic market. Obesity, defined by an extreme accumulation of body fat that poses a risk to health, is on the rise due to factors such as sedentary lifestyles, poor dietary habits, genetic factors, and environmental conditions encouraging calorie-dense diets and lack of physical activity. Therapies for peptide-based metabolic disorders aim to manage obesity and similar conditions by using peptides to regulate metabolic activity, enhance insulin sensitivity, and curb appetite, consequently improving patient health resolutions and diminishing the long-term health hazards linked to these chronic disorders. For example, The British Diabetic Association, widely recognized as a UK-based healthcare and research charity, reported in April 2024 that 4.4 million people in the UK are living with diabetes, and another estimated 1.2 million people may have undiagnosed type 2 diabetes. The registration data for 2022-23 indicates a rise of 167,822 from 2021-22. Therefore, the growing instance of obesity is a major factor propelling the peptide-based metabolic disorder therapeutics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16764&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Peptide Based Metabolic Disorders Therapeutics Market?
Top companies within the peptide-based metabolic disorder therapeutics market are focusing their efforts on creating innovative peptides for treatment to satisfy unmet medical requirements and broaden the scope of patient treatment. Biosimilars, specifically those for anti-diabetics, are therapeutic medicines modelled after existing peptide-based therapies used for diabetes. They come with similar safety and efficacy standards and could potentially reduce treatment expenses due to the competitive way they are priced. For example, Glenmark Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Lirafit, a biosimilar of the famous anti-diabetic medication Liraglutide, in India in January 2024. Lirafit is part of the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) class of medications. This group of medication reproduces the effect of the naturally present GLP-1 hormone, which is essential in controlling blood sugar levels. Lirafit underwent clinical trials to show its effectivity in reducing glycemic parameters and promoting weight loss, while also improving cardiovascular safety. These benefits are crucial in managing diabetes and related conditions like obesity and cardiovascular diseases.
What Are the Emerging Segments in the Peptide Based Metabolic Disorders Therapeutics Market?
The peptide based metabolic disorders therapeutics market covered in this report is segmented -
1) By Drug Type: Liraglutide, Exenatide, Other Drug Type
2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity
2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide
3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16764&type=smp
Who Are the Global Leaders in the Peptide Based Metabolic Disorders Therapeutics Market?
Major companies operating in the peptide based metabolic disorders therapeutics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Eli Lilly Company, Amgen Inc., Gilead Sciences Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Jazz Pharmaceuticals plc, Ipsen S.A, BioMarin Pharmaceutical Inc., Amarin Corporation plc, PolyPeptide Group
Which are the Top Profitable Regional Markets for the Peptide Based Metabolic Disorders Therapeutics Industry?
North America was the largest region in the peptide based metabolic disorders therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide based metabolic disorders therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16764
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Peptide Based Metabolic Disorders Therapeutics Market Landscape to 2034: Key Forces Shaping the Next Decade of Growth here
News-ID: 4138830 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Peptide
ShiLai Peptide to Invest $32 Million in State-of-the-Art Peptide Laboratory in H …
ShiLai Peptide's CEO, Luo Binhua, said the investment reflects the company's commitment to a "new science model" that integrates research-driven development, controlled production, and specialized customer support.
ShiLai Peptide [https://retatrutidesupplier.com/], a leading provider of high-purity, customizable research peptides, announced plans to invest $32 million to build a state-of-the-art peptide research and production laboratory in Hangzhou. The facility is designed to meet world-class GMP standards, aiming to strengthen ShiLai's global supply of…
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…
